Mutagenic Tests Confirm That New Acetylacetonate Pt(II) Complexes Induce Apoptosis in Cancer Cells Interacting with Nongenomic Biological Targets

Table 1

Net revertants/plate (mean ± SD) and MR (mutagenic ratio) of 1a, 2a, 2b complexes and cisplatin on TA98 and TA100 Salmonella typhimurium strains.

1a

2a

2b

Revertans/plate (mean ± SD)

MR

Revertans/plate (mean ± SD)

MR

Revertans/plate (mean ± SD)

MR

Revertans/plate (mean ± SD)

MR

Revertans/plate (mean ± SD)

MR

Revertans/plate (mean ± SD)

MR

TA98

TA100

TA98

TA100

TA98

TA100

Negative control (DMSO)

87.67 ± 16.8

114.67 ± 11.6

82.3 ± 9.6

128.67 ± 21.2

78.7 ± 11.6

119.33 ± 6.4

Positive control (cisplatin) >5 μg/plate

>400

>400

>400

>400

>400

>400

Dose 1 (0.01 μg/plate)

86 ± 5.6

0.98

62 ± 25.4

0.54

73 ± 1.4

0.89

121 ± 12.7

0.94

66.0 ± 5.6

0.84

141 ± 49.5

1.18

DOSE 2 (0.1 μg/plate)

93.5 ± 3.5

1.07

87 ± 5.7

0.76

99.0 ± 1.4

1.15

119.5 ± 2.1

0.93

97.5 ± 9.2

1.24

144.5 ± 3.5

1.21

DOSE 3 (0.5 μg/plate)

93.5 ± 0.7

1.07

88 ± 0

0.77

108.0 ± 14.1

1.31

134 ± 5.7

1.04

100 ± 1.4

1.27

156.5 ± 9.2

1.31

DOSE 4 (1 μg/plate)

90 ± 1.4

1.03

75.9 ± 9.2

0.66

118.0 ± 2.8

1.43

132 ± 8.5

1.03

116.5 ± 3.5

1.48

141 ± 24

1.18

DOSE 5 (5 μg/plate)

79 ± 2.8

0.90

98 ± 13.4

0.85

98.0 ± 5.6

1.19

132.5 ± 2.1

1.03

81.5 ± 9.6

1.04

142 ± 16.9

1.19

DOSE 6 (10 μg/plate)

106 ± 19.8

1.21

103 ± 29.7

0.90

122.0 ± 2.8

1.48

134.5 ± 3.5

1.05

125.5 ± 31.8

1.60

165 ± 9.9

1.38

DOSE 7 (20 μg/plate)

101.5 ± 14.8

1.16

111 ± 1.41

0.97

103.5 ± 12.0

1.26

116 ± 5.7

0.90

89 ± 4.2

1.13

146 ± 1.4

1.22

DOSE 8 (30 μg/plate)

14.5 ± 0.7

0.17

146.5 ± 21.9

1.28

114.5 ± 7.78

1.39

140 ± 4.2

1.09

109 ± 4.2

1.39

146 ± 19.8

1.22